Cited 8 times in
Antiproteinuric Effect of Losartan in Non-Diabetic Renal Disease Is Not Dependent on ACE Insertion/Deletion Polymorphism
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 한대석 | - |
dc.contributor.author | 최규헌 | - |
dc.contributor.author | 강신욱 | - |
dc.contributor.author | 김범석 | - |
dc.contributor.author | 박형천 | - |
dc.contributor.author | 최훈영 | - |
dc.contributor.author | 하성규 | - |
dc.date.accessioned | 2015-06-10T12:01:18Z | - |
dc.date.available | 2015-06-10T12:01:18Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 1420-4096 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/109047 | - |
dc.description.abstract | Background: The antiproteinuric effect of angiotensin-converting enzyme (ACE) inhibitors appears to vary depending on the ACE insertion (I)/deletion (D) genotype in non-diabetic nephropathy. This interaction may be overcome by using an angiotensin II receptor blocker. We evaluated the short-term antiproteinuric effect of losartan according to the ACE I/D genotype in patients with non-diabetic proteinuric renal diseases. Methods: Ninety-nine (II/ID/DD: 36/52/11) non-diabetic patients with overt proteinuria were enrolled. The patients received losartan 50 mg daily followed by 100 mg in two treatment periods each lasting 12 weeks. Clinical parameters including proteinuria were measured at baseline and at the end of each period. Results: At baseline each genotype (II/ID/DD) had comparable mean arterial blood pressure (mean ± SD) 103.2 ± 11.1/102.7 ± 10.6/104.1 ± 15.3; proteinuria (geometric mean, 95% CI, mg/day) 1,839 (1,518–2,227)/1,998 (1,683–2,372)/1,613 (1,072–2,427), and creatinine clearance (ml/min/1.73 m2) 65.7 ± 28.4/63.2 ± 27.8/68.8 ± 25.3, respectively. Both doses of losartan significantly lowered blood pressure and proteinuria (p < 0.05 vs. baseline), and losartan 100 mg was more effective than 50 mg in reducing proteinuria (52.5 ± 29.0 vs. 40.5 ± 30.8%, respectively, p = 0.001). No differences in the antiproteinuric effect of losartan was observed among the ACE I/D genotype. Losartan 100 mg demonstrated a comparable degree of mean arterial pressure (mean ± SD, %) (II/ID/DD, 13.3 ± 7.6/10.8 ± 9.8/13.0 ± 11.6, respectively, p = NS) and proteinuria reduction (mean, 95% CI) among the three genotypes (51.4% (40.3–62.5%)/53.4% (45.5–61.4%)/51.4% (40.0–63.8%), respectively, p = NS). Conclusion: Our data suggest that losartan provides a similar short-term antiproteinuric response for all three genotypes of ACE I/D genotype in non-diabetic proteinuric chronic renal disease. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | KIDNEY & BLOOD PRESSURE RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Angiotensin II Type 1 Receptor Blockers/administration & dosage* | - |
dc.subject.MESH | Blood Pressure/drug effects | - |
dc.subject.MESH | Diuretics/administration & dosage | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Deletion | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Losartan/administration & dosage* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Peptidyl-Dipeptidase A/genetics* | - |
dc.subject.MESH | Polymorphism, Genetic | - |
dc.subject.MESH | Prevalence | - |
dc.subject.MESH | Proteinuria/drug therapy* | - |
dc.subject.MESH | Proteinuria/epidemiology | - |
dc.subject.MESH | Proteinuria/genetics* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Antiproteinuric Effect of Losartan in Non-Diabetic Renal Disease Is Not Dependent on ACE Insertion/Deletion Polymorphism | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Park H.C. | - |
dc.contributor.googleauthor | Choi H.Y. | - |
dc.contributor.googleauthor | Kim B.S. | - |
dc.contributor.googleauthor | Kang S.W. | - |
dc.contributor.googleauthor | Choi K.H. | - |
dc.contributor.googleauthor | Ha S.K. | - |
dc.contributor.googleauthor | Lee H.Y. | - |
dc.contributor.googleauthor | Han D.S. | - |
dc.identifier.doi | 10.1159/000095736 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04272 | - |
dc.relation.journalcode | J01940 | - |
dc.identifier.eissn | 1423-0143 | - |
dc.identifier.pmid | 16960460 | - |
dc.identifier.url | http://www.karger.com/Article/Fulltext/95736 | - |
dc.subject.keyword | Angiotensin-converting enzyme gene polymorphism | - |
dc.subject.keyword | Losartan Nephropathy, non-diabetic | - |
dc.subject.keyword | Proteinuria | - |
dc.contributor.alternativeName | Han, Dae Suk | - |
dc.contributor.affiliatedAuthor | Han, Dae Suk | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 29 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 216 | - |
dc.citation.endPage | 224 | - |
dc.identifier.bibliographicCitation | KIDNEY & BLOOD PRESSURE RESEARCH, Vol.29(4) : 216-224, 2006 | - |
dc.identifier.rimsid | 50541 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.